RxDoctor Payments Data

Robert Chehade, MD

Gastroenterology · Concord, NHNPI 1174713275

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 38.1% of the total. Reporting peaked in 2023 at $407 and has fallen 98.5% since, to $6 in 2025.

$1,187in general payments, 2019–2025

Across 61 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$453
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$169
  • Bristol Myers Squibb$137
  • Pfizer$82
  • UCB, Inc.$69
  • Merck$54
  • plus $223 from 8 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,187 in reported general payments places this provider in the 60th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$90,994
Medicare patients
421
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide32$28,644
Mesalamine50$26,505
Ursodiol13$5,103
Colestipol Hcl38$3,306
Balsalazide Disodium12$3,067
Entecavir13$2,806
Budesonide EcBudesonide15$1,643
Omeprazole98$1,355
Mesalamine ErMesalamine16$1,349
Lubiprostone13$1,256
Azathioprine20$666
Pantoprazole Sodium55$602
Dicyclomine Hcl15$438
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$337
Sucralfate11$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$453$28,64432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →